Top

Published in:

Open Access 28-06-2023 | Pharmacokinetics | Original Research Article

Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis

Authors: Jeffrey G. Stark, Patrick K. Noonan, Robert H. Spencer, Sarbani Bhaduri, Stephen J. O’Connor, Frédérique Menzaghi

Published in: Clinical Pharmacokinetics | Issue 9/2023

Abstract

Background and Objective

Difelikefalin, a selective kappa-opioid receptor agonist, is the first approved treatment for moderate-to-severe pruritus in patients with end-stage renal disease (ESRD) on hemodialysis (HD) in the USA and Europe. The purpose of this open-label study was to investigate the pharmacokinetics and disposition of [¹⁴C]difelikefalin following a single intravenous dose in subjects with normal renal function and subjects on HD.

Methods

Twelve adult males (n = 6 healthy subjects; n = 6 subjects on HD) received single intravenous doses of [¹⁴C]difelikefalin containing 100 µCi (total doses of 1.7–3.0 μg/kg difelikefalin). Blood, urine, feces, and dialysate samples (when applicable) were collected after dosing.

Results

The median time to maximum concentration was similar for HD and healthy subjects, occurring at 5 min post-dose. The mean area under the concentration–time curve (AUC) was approximately 11-fold higher in HD versus healthy subjects; mean plasma half-life was 38.0 h and 2.6 h, respectively. In healthy subjects, 80.5% of the dose was recovered in urine, and 11.3% was recovered in feces. In subjects on HD, 58.8% of the dose was recovered in feces, and 19.5% was recovered in dialysate [for subjects on HD with residual kidney function (n = 3), 11.2% was recovered in urine]. Based on plasma AUC_last, parent [¹⁴C]difelikefalin was the most abundant analyte in systemic circulation (> 99% of total exposure) for both cohorts. Metabolite profiles in urine and feces suggested minimal metabolism of the parent compound.

Conclusion

In subjects on HD, difelikefalin total exposure was higher and plasma half-life was longer compared with subjects with intact renal function. Metabolism was low in both healthy subjects and subjects on HD, with unchanged drug representing > 99% of systemic circulation; however, the route of excretion was primarily into urine versus feces in healthy subjects, and feces versus dialysate in subjects on HD.

Registration

ClinicalTrials.gov NCT03947970.

Available only for authorised users

Albert-Vartanian A, Boyd MR, Hall AL, Morgado SJ, Nguyen E, Nguyen VP, et al. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther. 2016;41:371–82. https://doi.org/10.1111/jcpt.12404. CrossRefPubMed

Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382:222–32. https://doi.org/10.1056/NEJMoa1912770. CrossRefPubMed

Wooldridge TD, Mccafferty K, Schoemig M, Szabolcs Csiky B, Zwiech R, Wen W, et al. Efficacy and safety of difelikefalin for moderate-to-severe CKD–associated pruritus: a global phase 3 study in hemodialysis patients (KALM-2) [abstract FR-OR24]. J Am Soc Nephrol. 2020;31(suppl):22–3.

Korsuva (difelikefalin) [package insert]. Stamford: Cara Therapeutics, Inc.; 2021.

Fishbane S, Mathur V, Germain MJ, Shirazian S, Bhaduri S, Munera C, et al. Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients. Kidney Int Rep. 2020;5:600–10. https://doi.org/10.1016/j.ekir.2020.01.006. CrossRefPubMedPubMedCentral

Fishbane S, Wen W, Munera C, Lin R, Bagal S, McCafferty K, et al. Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program. Kidney Med. 2022;4: 100513. https://doi.org/10.1016/j.xkme.2022.100513. CrossRefPubMedPubMedCentral

Viscusi ER, Torjman MC, Munera CL, Stauffer JW, Setnik BS, Bagal SN. Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: a randomized, double-blind, placebo-controlled trial. Clin Transl Sci. 2021;14(5):1886–93. https://doi.org/10.1111/cts.13042. CrossRefPubMedPubMedCentral

Shram MJ, Spencer RH, Qian J, Munera CL, Lewis ME, Henningfield JE, et al. Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users. Clin Transl Sci. 2022;15:535–47. https://doi.org/10.1111/cts.13173. CrossRefPubMed

Satti MZ, Arshad D, Javed H, Shahroz A, Tahir Z, Ahmed MMH, et al. Uremic pruritus: prevalence and impact on quality of life and depressive symptoms in hemodialysis patients. Cureus. 2019;11: e5178. https://doi.org/10.7759/cureus.5178. CrossRefPubMedPubMedCentral

10.

Rehman IU, Lai PSM, Lim SK, Lee LH, Khan TM. Sleep disturbance among Malaysian patients with end-stage renal disease with pruritus. BMC Nephrol. 2019;20:102. https://doi.org/10.1186/s12882-019-1294-1. CrossRefPubMedPubMedCentral

11.

Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus—new perspectives and insights from recent trials. Nephrol Dial Transplant. 2002;17:1558–63. https://doi.org/10.1093/ndt/17.9.1558. CrossRefPubMed

12.

Sukul N, Speyer E, Tu C, Bieber BA, Li Y, Lopes AA, et al. Pruritus and patient reported outcomes in non-dialysis CKD. Clin J Am Soc Nephrol. 2019;14:673–81. https://doi.org/10.2215/CJN.09600818. CrossRefPubMedPubMedCentral

13.

Ting SW, Fan PC, Lin YS, Lin MS, Lee CC, Kuo G, et al. Uremic pruritus and long-term morbidities in the dialysis population. PLoS ONE. 2020;15:e0241088. https://doi.org/10.1371/journal.pone.0241088. CrossRefPubMedPubMedCentral

14.

Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006;69:1626–32. https://doi.org/10.1038/sj.ki.5000251. CrossRefPubMed

15.

Pisoni RL, Wikström B, Elder SJ, Akizawa T, Asano Y, Keen ML, et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006;21:3495–505. https://doi.org/10.1093/ndt/gfl461. CrossRefPubMed

16.

Rayner HC, Larkina M, Wang M, Graham-Brown M, van der Veer SN, Ecder T, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol. 2017;12:2000–7. https://doi.org/10.2215/CJN.03280317. CrossRefPubMedPubMedCentral

17.

Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 2006;21:749–55. https://doi.org/10.1093/ndt/gfi204. CrossRefPubMed

18.

Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J Dermatol. 2011;165:5–17. https://doi.org/10.1111/j.1365-2133.2011.10217.x. CrossRefPubMedPubMedCentral

19.

Phan NQ, Lotts T, Antal A, Bernhard JD, Stander S. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol. 2012;92:555–60. https://doi.org/10.2340/00015555-1353. CrossRefPubMed

20.

Beumer JH, Beijnen JH, Schellens JH. Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet. 2006;45:33–58. https://doi.org/10.2340/00015555-1353. CrossRefPubMed

21.

McEwen A. The human ADME study. In: Hock FJ, Gralinski MR, editors. Drug discovery and evaluation: methods in clinical pharmacology. Cham: Springer International Publishing; 2017. p. 1–34.

Title: Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis
Authors: Jeffrey G. Stark
Patrick K. Noonan
Robert H. Spencer
Sarbani Bhaduri
Stephen J. O’Connor
Frédérique Menzaghi
Publication date: 28-06-2023
Publisher: Springer International Publishing
Keywords: Pharmacokinetics
Pruritus
Published in: Clinical Pharmacokinetics / Issue 9/2023
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-023-01262-2

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis

Abstract

Background and Objective

Methods

Results

Conclusion

Registration

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Abstract

Background and Objective

Methods

Results

Conclusion

Registration

Please log in to get access to this content

Other articles of this Issue 9/2023

Significant Effects of Renal Function on Mycophenolic Acid Total Clearance in Pediatric Kidney Transplant Recipients with Population Pharmacokinetic Modeling

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults

Correction: A Review of Population Pharmacokinetic Analyses of Linezolid

Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment

Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients

Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement